02 June 2023 : Clinical Research
Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers
Dragana Miletić1ADEF*, Marija Kraljević1ADEF, Emir Sokolović2CDE, Majana Soče3B, Marijana Milović-Kovačević4B, Simonida Bobić4B, Timur Cerić2ABDE, Stjepko Pleština3A, Semir Bešlija2AE, Inga Marijanović15ADEDOI: 10.12659/MSM.940356
Med Sci Monit 2023; 29:e940356
Table 3 First-line treatment of the patients with metastatic HER2-positive breast cancer in 4 oncology centers in high-income and upper-middle-income countries.
| Initial treatment (first-line) | Site | |||
|---|---|---|---|---|
| HICZagreb (Croatia)n (%) | UMICBelgrade (Serbia)n (%) | UMICSarajevo (Bosnia and Herzegovina)n (%) | UMICMostar (Bosnia and Herzegovina)n (%) | |
| Taxane-based chemotherapy + dual HER2 blockade | 15 (35.7) | 12 (16.9) | 10 (34.5) | 7 (25.0) |
| Chemotherapy-only | 0 | 57 (80.3) | 0 | 5 (17.9) |
| Chemotherapy + Trastuzumab | 2 (4.8) | 0 | 13 (44.8) | 8 (28.6) |
| Hormonal therapy | 0 | 2 (2.8) | 1 (3.4) | 8 (28.6) |
| Hormonal therapy + dual HER2 blockade | 0 | 0 | 2 (6.9) | 0 |
| Hormonal therapy + Trastuzumab | 1 (2.4) | 0 | 2 (6.9) | 0 |
| Trastuzumab | 0 | 0 | 1 (3.4) | 0 |
| Taxanes-based chemotherapy + dual HER2 blockade + hormonal therapy | 23 (54.8) | 0 | 0 | 0 |
| Chemotherapy + dual HER2 blockade + hormonal therapy | 1 (2.4) | 0 | 0 | 0 |
| HIC – high-income country; UMIC – upper-middle-income country. | ||||